GSK plc Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - GSK plc is facing a class action lawsuit from investors due to alleged misleading statements and failure to disclose critical information regarding the carcinogenic risks associated with its heartburn medication, Zantac, during the specified class period [1][4]. Company Overview - GSK and its subsidiaries are involved in the research, development, and manufacturing of vaccines, specialty, and general medicines aimed at preventing and treating diseases [3]. Legal Allegations - The lawsuit claims that GSK was aware of the carcinogenic compound N-nitrosodimethylamine (NDMA) produced by Zantac's active ingredient, ranitidine, since 1982 but failed to disclose this information [3][6]. - GSK's Zantac generated billions in revenue over two decades, and the company is accused of making false or misleading statements throughout the class period [3][4]. Financial Impact - A Deutsche Bank report on August 10, 2022, estimated GSK's potential liability exposure between $5 billion and$10 billion, leading to a more than 10% drop in GSK ADRs [4]. - Following GSK's acknowledgment of potential liability exposure between $1 billion and$10 billion on August 15, 2022, GSK ADRs declined an additional 3% [5].